The combined administration of mesalamine and PTX produced the most pronounced effect, significantly reducing IL‐6 and STAT3 levels by 57.93% (F = 505.4, p < 0.0001) and 68.91% (F = 153.3, p < 0.0001), respectively, in comparison to the colitis group. The gene discussed is IL6; the disease is colitis.